dc.contributor.author |
Ahmadzadehfar, Hojjat
|
|
dc.contributor.author |
Rahbar, Kambiz
|
|
dc.contributor.author |
Baum, Richard P.
|
|
dc.contributor.author |
Seifert, Robert
|
|
dc.contributor.author |
Kessel, Katharina
|
|
dc.contributor.author |
Bogemann, Martin
|
|
dc.contributor.author |
Kulkarni, Harshad R.
|
|
dc.contributor.author |
Zhang, Jingjing
|
|
dc.contributor.author |
Gerke, Carolin
|
|
dc.contributor.author |
Fimmers, Rolf
|
|
dc.contributor.author |
Kratochwil, Clemens
|
|
dc.contributor.author |
Rathke, Hendrik
|
|
dc.contributor.author |
Ilhan, Harun
|
|
dc.contributor.author |
Maffey-Steffan, Johanna
|
|
dc.contributor.author |
Sathekge, Mike Machaba
|
|
dc.contributor.author |
Kabasakal, Levent
|
|
dc.contributor.author |
Osvaldo Garcia-Perez, Francisco
|
|
dc.contributor.author |
Kairemo, Kalevi
|
|
dc.contributor.author |
Maharaj, Masha
|
|
dc.contributor.author |
Paez, Diana
|
|
dc.contributor.author |
Virgolini, Irene
|
|
dc.date.accessioned |
2021-02-15T07:56:50Z |
|
dc.date.available |
2021-02-15T07:56:50Z |
|
dc.date.issued |
2021-01 |
|
dc.description |
This article is part of the Topical Collection on Oncology - Genitourinary |
en_ZA |
dc.description.abstract |
Please read abstract in the article. |
en_ZA |
dc.description.department |
Nuclear Medicine |
en_ZA |
dc.description.librarian |
am2021 |
en_ZA |
dc.description.sponsorship |
Open Access funding provided by Projekt DEAL. |
en_ZA |
dc.description.uri |
http://link.springer.com/journal/259 |
en_ZA |
dc.identifier.citation |
Ahmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) European Journal of Nuclear Medicine and Molecular Imaging, 48, 113–122 (2021). https://doi.org/10.1007/s00259-020-04797-9. |
en_ZA |
dc.identifier.issn |
1619-7070 (print) |
|
dc.identifier.issn |
1619-7089 (online) |
|
dc.identifier.other |
10.1007/s00259-020-04797-9 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/78552 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Springer |
en_ZA |
dc.rights |
© The Author(s) 2020.
This article is licensed under a Creative Commons
Attribution 4.0 International License. |
en_ZA |
dc.subject |
Radioligand therapy |
en_ZA |
dc.subject |
Lu-PSMA |
en_ZA |
dc.subject |
Chemotherapy |
en_ZA |
dc.subject |
Castration-resistant prostate cancer (CRPC) |
en_ZA |
dc.subject |
Metastatic CRPC (mCRPC) |
en_ZA |
dc.title |
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) |
en_ZA |
dc.type |
Article |
en_ZA |